Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Proteins can exist in two forms: left-handed (L) or right-handed (D); however, for indeterminate reasons life on this planet only uses the L-form. When studied in more detail, both protein forms possess identical physiochemical and biological properties. Yet, D-proteins show minimal proteolytic degradation and fail to elicit immune responses in animals, due to their unnatural arrangement for recognition in biological systems. Accordingly, the proposed project seeks to develop synthetic D-proteins as biopharmaceutical molecules. We will utilize a method of high-throughput selection, previously established for selection of antibodies, to isolate D-proteins to target cellular receptors involved in cancer. In this regard, D-protein therapeutics will allow for longer circulation of peptide drugs in the body, and also render them less immunogenic and toxic. More exciting, is our collaboration with the CCAB, which will bridge the research and discovery with industry partners to enable the accelerated delivery of D-protein as therapies.
Jason Moffat
Gallo Eugenio
University of Toronto
Biochemistry / Molecular biology
Pharmaceuticals
University of Toronto
Elevate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.